Abstract:Current melanoma treatment have limitations of relapse. BH3 mimetics against BCL-2 family members have gained excitement with recent success in hematological cancers. However, single drug BH3 therapy not effective in melanoma due to escape by the anti-apoptotic protein MCL-1 and/or survival of Melanoma Initiating Cells (MICs). Melanoma progression correlates with increase in Dynamin-related protein 1 (DRP1). DRP1 interacts with BCL-2 family members, but its potential effects on BH3 mimetic treatment is not def… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.